Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Vala Kafil, Amir Ata Saei, Mohammad Reza Tohidkia, Jaleh Barar & Yadollah Omidi. (2020) Immunotargeting and therapy of cancer by advanced multivalence antibody scaffolds. Journal of Drug Targeting 28:10, pages 1018-1033.
Read now
Read now
Junnan Tang, Deliang Shen, Jinying Zhang, Frances S Ligler & Ke Cheng. (2015) Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done. Expert Opinion on Biological Therapy 15:9, pages 1251-1255.
Read now
Read now
Tanja D de Gruijl, Axel B Janssen & Victor W van Beusechem. (2015) Arming oncolytic viruses to leverage antitumor immunity. Expert Opinion on Biological Therapy 15:7, pages 959-971.
Read now
Read now
Carter M Suryadevara, Patrick C Gedeon, Luis Sanchez-Perez, Terence Verla, Christopher Alvarez-Breckenridge, Bryan D Choi, Peter E Fecci & John H Sampson. (2015) Are BiTEs the “missing link” in cancer therapy?. OncoImmunology 4:6.
Read now
Read now
Xiufeng Wu, Arlene J Sereno, Flora Huang, Steven M Lewis, Ricky L Lieu, Caroline Weldon, Carina Torres, Cody Fine, Micheal A Batt, Jonathan R Fitchett, Andrew L Glasebrook, Brian Kuhlman & Stephen J Demarest. (2015) Fab-based bispecific antibody formats with robust biophysical properties and biological activity. mAbs 7:3, pages 470-482.
Read now
Read now
Mahiuddin Ahmed, Ming Cheng, Irene Y Cheung & Nai-Kong V Cheung. (2015) Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. OncoImmunology 4:4.
Read now
Read now
Roland B Walter. (2014) Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Review of Hematology 7:3, pages 317-319.
Read now
Read now
Diane L Rossi, Edmund A Rossi, Thomas M Cardillo, David M Goldenberg & Chien-Hsing Chang. (2014) A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. mAbs 6:2, pages 381-391.
Read now
Read now
Deepa Kolaseri Krishnadas, Fanqi Bai & Kenneth G Lucas. (2013) Cancer testis antigen and immunotherapy. ImmunoTargets and Therapy 2, pages 11-19.
Read now
Read now
Bryan D Choi, Patrick C Gedeon, Luis Sanchez-Perez, Darell D Bigner & John H Sampson. (2013) Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. OncoImmunology 2:12.
Read now
Read now
Patrick C Gedeon, Bryan D Choi, Tiffany R Hodges, Duane A Mitchell, Darell D Bigner & John H Sampson. (2013) An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Review of Clinical Pharmacology 6:4, pages 375-386.
Read now
Read now
Bryan D. Choi, Ira Pastan, Darell D Bigner & John H. Sampson. (2013) A novel bispecific antibody recruits T cells to eradicate tumors in the “immunologically privileged” central nervous system. OncoImmunology 2:4.
Read now
Read now
Divaya Bhutani & Ulka N Vaishampayan. (2013) Monoclonal antibodies in oncology therapeutics: present and future indications. Expert Opinion on Biological Therapy 13:2, pages 269-282.
Read now
Read now
Articles from other publishers (59)
Radhika Takiar & Tycel J. Phillips. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal
123
145
.
Joshua F. Meckler, Daniel J. Levis, Daniel P. Vang & Joseph M. Tuscano. (2023) A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model. Cancer Immunology, Immunotherapy 72:9, pages 2939-2948.
Crossref
Crossref
Xingliang Fang, Jinfang Xu, Ketao Jin & Jun Qian. (2023) Combining of immunotherapeutic approaches with chemotherapy for treatment of gastric cancer: Achievements and limitations. International Immunopharmacology 118, pages 110062.
Crossref
Crossref
Fatemeh Nasiri, Mehrasa Kazemi, Seyed Mohamad Javad Mirarefin, Maral Mahboubi Kancha, Milad Ahmadi Najafabadi, Faeze Salem, Setareh Dashti Shokoohi, Sahar Evazi Bakhshi, Pouya Safarzadeh Kozani & Pooria Safarzadeh Kozani. (2022) CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. Frontiers in Immunology 13.
Crossref
Crossref
Giorgia Guaitoli, Giovanni Neri, Eleonora Cabitza, Salvatore Natalizio, Luciana Mastrodomenico, Sabrina Talerico, Lucia Trudu, Chiara Lauro, Chiara Chiavelli, Maria Cristina Baschieri, Alessio Bruni, Massimo Dominici & Federica Bertolini. (2022) Dissecting Immunotherapy Strategies for Small Cell Lung Cancer: Antibodies, Ionizing Radiation and CAR-T. International Journal of Molecular Sciences 23:21, pages 12728.
Crossref
Crossref
Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, Milad Ahmadi Najafabadi, Fatemeh Yousefi, Seyed Mohamad Javad Mirarefin & Fatemeh Rahbarizadeh. (2022) Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?. Frontiers in Immunology 13.
Crossref
Crossref
Lydia G. White, Hannah E. Goy, Alinor J. Rose & Alexander D. McLellan. (2022) Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours. Cancers 14:4, pages 978.
Crossref
Crossref
Gabriele Antonarelli, Federica Giugliano, Chiara Corti, Matteo Repetto, Paolo Tarantino & Giuseppe Curigliano. (2021) Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals 14:9, pages 884.
Crossref
Crossref
Hany E. Marei, Asmaa Althani, Nahla Afifi, Anwarul Hasan, Thomas Caceci, Giacomo Pozzoli & Carlo Cenciarelli. (2021) Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme. Cancer Medicine 10:15, pages 5019-5030.
Crossref
Crossref
Karthik Nath & Maher K. Gandhi. (2021) Targeted Treatment of Follicular Lymphoma. Journal of Personalized Medicine 11:2, pages 152.
Crossref
Crossref
G. Fucà, A. Spagnoletti, M. Ambrosini, F. de Braud & M. Di Nicola. (2021) Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy. ESMO Open 6:1, pages 100046.
Crossref
Crossref
Derek C. Church & Jonathan K. Pokorski. (2020) Cell Engineering with Functional Poly(oxanorbornene) Block Copolymers. Angewandte Chemie International Edition 59:28, pages 11379-11383.
Crossref
Crossref
Derek C. Church & Jonathan K. Pokorski. (2020) Cell Engineering with Functional Poly(oxanorbornene) Block Copolymers. Angewandte Chemie 132:28, pages 11475-11479.
Crossref
Crossref
Sumeyye Cavdarli, Philippe Delannoy & Sophie Groux-Degroote. (2020) O-acetylated Gangliosides as Targets for Cancer Immunotherapy. Cells 9:3, pages 741.
Crossref
Crossref
Peilu Liu, Xuan Gao, Victor Lundin, Catherine Shi, Yilma Adem, Kevin Lin, Guoying Jiang, Yung-Hsiang Kao, Feng Yang, David Michels, Alan G. Marshall & Hui-Min Zhang. (2019) Probing the Impact of the Knob-into-Hole Mutations on the Structure and Function of a Therapeutic Antibody. Analytical Chemistry 92:1, pages 1582-1588.
Crossref
Crossref
Dan Li, Xue Li, Wei-Lin Zhou, Yong Huang, Xiao Liang, Lin Jiang, Xiao Yang, Jie Sun, Zonghai Li, Wei-Dong Han & Wei Wang. (2019) Genetically engineered T cells for cancer immunotherapy. Signal Transduction and Targeted Therapy 4:1.
Crossref
Crossref
Bryan D. Choi, Xiaoling Yu, Ana P. Castano, Amanda A. Bouffard, Andrea Schmidts, Rebecca C. Larson, Stefanie R. Bailey, Angela C. Boroughs, Matthew J. Frigault, Mark B. Leick, Irene Scarfò, Curtis L. Cetrulo, Shadmehr Demehri, Brian V. Nahed, Daniel P. Cahill, Hiroaki Wakimoto, William T. Curry, Bob S. Carter & Marcela V. Maus. (2019) CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nature Biotechnology 37:9, pages 1049-1058.
Crossref
Crossref
Eun Sook Lee, Jung Min Shin, Soyoung Son, Hyewon Ko, Wooram Um, Seok Ho Song, Jae Ah Lee & Jae Hyung Park. (2019) Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. Advanced Healthcare Materials, pages 1801320.
Crossref
Crossref
Cynthia Kassab, Brittany Parker Kerrigan, Hillary Caruso, Sanaalarab Al Enazy & Amy B. Heimberger. 2019. Nervous System Drug Delivery. Nervous System Drug Delivery
297
334
.
Wenwen Sun, Na Zhang, Yujie Zhang, Zonghong Shao, Lu Gong & Wei Wei. (2018) Immunophenotypes and clinical features of lymphocytes in the labial gland of primary Sjogren's syndrome patients. Journal of Clinical Laboratory Analysis 32:9.
Crossref
Crossref
Xiaolong Zhang, Yuanyuan Yang, Dongmei Fan & Dongsheng Xiong. (2017) The development of bispecific antibodies and their applications in tumor immune escape. Experimental Hematology & Oncology 6:1.
Crossref
Crossref
Abbas Alibakhshi, Fatemeh Abarghooi Kahaki, Shahrzad Ahangarzadeh, Hajar Yaghoobi, Fatemeh Yarian, Roghaye Arezumand, Javad Ranjbari, Ahad Mokhtarzadeh & Miguel de la Guardia. (2017) Targeted cancer therapy through antibody fragments-decorated nanomedicines. Journal of Controlled Release 268, pages 323-334.
Crossref
Crossref
Ju Yang, Jing Yan & Baorui Liu. (2017) Targeting EGFRvIII for glioblastoma multiforme. Cancer Letters 403, pages 224-230.
Crossref
Crossref
Weidong Jiang, Scott Liu & Ziyang Zhong. 2016. Biosimilars of Monoclonal Antibodies. Biosimilars of Monoclonal Antibodies
427
458
.
Feifei Luo, Jiawen Qian, Jiao Yang, Yuting Deng, Xiujuan Zheng, Jie Liu & Yiwei Chu. (2016) Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2+ gastric cancer. Cell Research 26:7, pages 850-853.
Crossref
Crossref
Frank J. Warnders, Stijn J.H. Waaijer, Martin Pool, Marjolijn N. Lub–de Hooge, Matthias Friedrich, Anton G.T. Terwisscha van Scheltinga, Petra Deegen, Sabine K. Stienen, Peter C. Pieslor, H.Kam Cheung, Jos G.W. Kosterink & Elisabeth G.E. de Vries. (2016) Biodistribution and PET Imaging of Labeled Bispecific T Cell–Engaging Antibody Targeting EpCAM. Journal of Nuclear Medicine 57:5, pages 812-817.
Crossref
Crossref
Daniel Regan, Amanda Guth, Jonathan Coy & Steven Dow. (2016) Cancer immunotherapy in veterinary medicine: Current options and new developments. The Veterinary Journal 207, pages 20-28.
Crossref
Crossref
J.M. Redman, E.M. Hill, D. AlDeghaither & L.M. Weiner. (2015) Mechanisms of action of therapeutic antibodies for cancer. Molecular Immunology 67:2, pages 28-45.
Crossref
Crossref
Kimberly H. Harrington, Chelsea J. Gudgeon, George S. Laszlo, Kathryn J. Newhall, Angus M. Sinclair, Stanley R. Frankel, Roman Kischel, Guang Chen & Roland B. Walter. (2015) The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk. PLOS ONE 10:8, pages e0135945.
Crossref
Crossref
G S Laszlo, C J Gudgeon, K H Harrington & R B Walter. (2015) T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. Blood Cancer Journal 5:8, pages e340-e340.
Crossref
Crossref
Jianxuan Zou, Dan Chen, Yunhui Zong, Sisi Ye, Jinle Tang, Huimin Meng, Gangli An, Xingding Zhang & Lin Yang. (2015)
Immunotherapy based on bispecific T‐cell engager with
hIgG
1 Fc sequence as a new therapeutic strategy in multiple myeloma
. Cancer Science 106:5, pages 512-521.
Crossref
Crossref
Kenneth M. Prentice, Alison Wallace & Catherine M. Eakin. (2015) Inline Protein A Mass Spectrometry for Characterization of Monoclonal Antibodies. Analytical Chemistry 87:4, pages 2023-2028.
Crossref
Crossref
Michelle H. Nelson & Chrystal M. Paulos. (2014) Novel immunotherapies for hematologic malignancies. Immunological Reviews 263:1, pages 90-105.
Crossref
Crossref
Ke Cheng, Deliang Shen, M. Taylor Hensley, Ryan Middleton, Baiming Sun, Weixin Liu, Geoffrey De Couto & Eduardo Marbán. (2014) Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting. Nature Communications 5:1.
Crossref
Crossref
D. A. Reardon, G. Freeman, C. Wu, E. A. Chiocca, K. W. Wucherpfennig, P. Y. Wen, E. F. Fritsch, W. T. Curry, J. H. Sampson & G. Dranoff. (2014) Immunotherapy advances for glioblastoma. Neuro-Oncology 16:11, pages 1441-1458.
Crossref
Crossref
Takao Hamakubo, Osamu Kusano-Arai & Hiroko Iwanari. (2014) Generation of antibodies against membrane proteins. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1844:11, pages 1920-1924.
Crossref
Crossref
George S. Laszlo, Elihu H. Estey & Roland B. Walter. (2014) The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Reviews 28:4, pages 143-153.
Crossref
Crossref
George S. LaszloChelsea J. GudgeonKimberly H. HarringtonJustine Dell’AringaKathryn J. NewhallGary D. MeansAngus M. SinclairRoman KischelStanley R. Frankel & Roland B. Walter. (2014) Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 123:4, pages 554-561.
Crossref
Crossref
Weizao Chen, Yang Feng, Ponraj Prabakaran, Tianlei Ying, Yanping Wang, Jianping Sun, Camila D. S. Macedo, Zhongyu Zhu, Yuxian He, Victoria R. Polonis & Dimiter S. Dimitrov. (2014) Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains. Journal of Virology 88:2, pages 1125-1139.
Crossref
Crossref
Steven M Albelda & Steve H Thorne. (2014) Giving Oncolytic Vaccinia Virus More BiTE. Molecular Therapy 22:1, pages 6-8.
Crossref
Crossref
Jingting Jiang, Changping Wu & Binfeng Lu. (2013) Cytokine-induced killer cells promote antitumor immunity. Journal of Translational Medicine 11:1.
Crossref
Crossref
Lei Wang, Yanran He, Ge Zhang, Juan Ma, Changzhen Liu, Wen He, Wei Wang, Huamin Han, Bhargavi M. Boruah & Bin Gao. (2013) Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody. PLoS ONE 8:9, pages e75589.
Crossref
Crossref
Bryan D. Choi, Patrick C. Gedeon, James E. HerndonIIII, Gary E. Archer, Elizabeth A. Reap, Luis Sanchez-Perez, Duane A. Mitchell, Darell D. Bigner & John H. Sampson. (2013) Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody. Cancer Immunology Research 1:3, pages 163-167.
Crossref
Crossref
Bryan D. Choi, Patrick C. Gedeon, Chien-Tsun Kuan, Luis Sanchez-Perez, Gary E. Archer, Darell D. Bigner & John H. Sampson. (2013) Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. Journal of Immunological Methods 395:1-2, pages 14-20.
Crossref
Crossref
Stanley R Frankel & Patrick A Baeuerle. (2013) Targeting T cells to tumor cells using bispecific antibodies. Current Opinion in Chemical Biology 17:3, pages 385-392.
Crossref
Crossref
M Aigner, J Feulner, S Schaffer, R Kischel, P Kufer, K Schneider, A Henn, B Rattel, M Friedrich, P A Baeuerle, A Mackensen & S W Krause. (2012) T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 27:5, pages 1107-1115.
Crossref
Crossref
Philippe Fournier & Volker Schirrmacher. (2012) Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer. BioDrugs 27:1, pages 35-53.
Crossref
Crossref
Bryan D. Choi, Chien-Tsun KuanMingqing CaiGary E. ArcherDuane A. MitchellPatrick C. Gedeon, Luis Sanchez-PerezIra Pastan, Darell D. BignerJohn H. Sampson. (2012) Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences 110:1, pages 270-275.
Crossref
Crossref
Rodney A. Prell, Donna W. Lee, Wendy G. Halpern & Anu V. Connor. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
343
371
.
Li Wei, Fan DongMei, Yang Ming, Shi RuiZan, Yan Yan, Jiang Linlin, Yan Cihui, Li Shuangjing, Wang Min, Wang Jianxiang & Xiong DongSheng. (2012) Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity. Cellular Oncology 35:6, pages 423-434.
Crossref
Crossref
S.-R. Kuo, L. Wong & J.-S. Liu. (2012) Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Engineering Design and Selection 25:10, pages 561-570.
Crossref
Crossref
Josée Golay & Martino Introna. (2012) Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. Archives of Biochemistry and Biophysics 526:2, pages 146-153.
Crossref
Crossref
M.A. Ströhlein & M.M. Heiss. (2012) Bispezifische AntikörperBispecific antibodies. Der Onkologe 18:9, pages 779-787.
Crossref
Crossref
Huiting Cui, Joshua D. Thomas, Terrence R. BurkeJr.Jr. & Christoph Rader. (2012) Chemically Programmed Bispecific Antibodies That Recruit and Activate T Cells. Journal of Biological Chemistry 287:34, pages 28206-28214.
Crossref
Crossref
Nicholas P. Restifo, Mark E. Dudley & Steven A. Rosenberg. (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology 12:4, pages 269-281.
Crossref
Crossref
Andrea Kiessling, Rebekka Wehner, Susanne Füssel, Michael Bachmann, Manfred P. Wirth & Marc Schmitz. (2012) Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer. Cancers 4:1, pages 193-217.
Crossref
Crossref
Katja Van HerleJacinta M. Behne, Andre Van HerleTerrence F. Blaschke, Terry J. Smith & Michael R. Yeaman. (2012) Integrative Continuum: Accelerating Therapeutic Advances in Rare Autoimmune Diseases. Annual Review of Pharmacology and Toxicology 52:1, pages 523-547.
Crossref
Crossref
Roberta E Burden, Jill Caswell, Francois Fay & Christopher J Scott. (2012) Recent advances in the application of antibodies as therapeutics. Future Medicinal Chemistry 4:1, pages 73-86.
Crossref
Crossref
Deron R. Herr. 2012. International Review of Cell and Molecular Biology Volume 297. International Review of Cell and Molecular Biology Volume 297
45
81
.